HPV33 E6 Polyclonal Antibody, PE-Cy7 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-2968R-PE-Cy7 |
| Product Name | HPV33 E6 Polyclonal Antibody, PE-Cy7 Conjugated |
| Applications |
WB
|
| Specificity | This antibody will detect E6 in HPV33, HPV58, and Alphapapillomavirus 9. |
| Reactivity | Virus |
| Specifications | |
| Conjugation | PE-Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human HPV33 E6 protein |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Synonyms | E6 protein [Human papillomavirus type 33]; Human Papilloma Virus; Human papillomavirus type 33; Human papillomavirus type 33; Protein 33; HPV33-E6 protein; HPV33 E6 protein; VE6_HPV33. |
| Background | Human papilloma viruses (HPVs) can be classified as either high risk or low risk according to their association with cancer. HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types. Approximately 90% of cervical cancers contain HPV DNA of the high risk types. Mutational analysis have shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function. The specific interactions of the E6 and E7 proteins with p53 and pRB, respectively, correlate with HPV high and low risk classifications. The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro. Human papillomaviruses (HPV) are small DNA viruses which infect epithelia of the skin and mucosa. Over 90 types have been identified and they mostly cause a variety of benign lesions such as warts and verrucae. However, some subtypes, notably types 16 and 18, 31 and 33, have been confirmed as agents which cause cervical cancer. The E6 protein is a transcriptional transactivator. Binds double-stranded DNA. This protein may be involved in the oncogenic potential of this virus (cervical neoplasia-associated virus). |
| Application Dilution | |
| WB | 1:300-5000 |
Frequently asked questions
Which applications is HPV33 E6 Polyclonal Antibody, PE-Cy7 Conjugated (bs-2968R-PE-Cy7) validated for, and at what dilution?
bs-2968R-PE-Cy7 is validated for WB (1:300-5000). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does HPV33 E6 Polyclonal Antibody, PE-Cy7 Conjugated (bs-2968R-PE-Cy7) react with?
Tested reactivity: Virus.
How should bs-2968R-PE-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise HPV33 E6 Polyclonal Antibody, PE-Cy7 Conjugated (bs-2968R-PE-Cy7)?
KLH conjugated synthetic peptide derived from human HPV33 E6 protein
What are the excitation and emission wavelengths of the PE-Cy7 conjugate (bs-2968R-PE-Cy7)?
PE-Cy7 on bs-2968R-PE-Cy7: excitation / emission 488nm/780nm.